EcoDrugPlus

Transient Receptor Potential Cation Channel Subfamily A Member 1

Ensembl ID : ENSRBIG00000028140
Gene Symbol: TRPA1
4 Cross references
226 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Transient Receptor Potential Cation Channel Subfamily M Member 8

Ensembl ID : ENSRBIG00000038917
Gene Symbol: TRPM8
4 Cross references
158 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Transient Receptor Potential Cation Channel Subfamily V Member 1

Ensembl ID : ENSRBIG00000043697
Gene Symbol: TRPV1
4 Cross references
134 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Translocator Protein

Ensembl ID : ENSRBIG00000044885
Gene Symbol: TSPO
4 Cross references
126 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Transthyretin

Ensembl ID : ENSRBIG00000042966
Gene Symbol: TTR
4 Cross references
164 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Tryptophan Hydroxylase 1

Ensembl ID : ENSRBIG00000008098
Gene Symbol: TPH1
4 Cross references
255 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Tubulin Alpha-1 Chain

Ensembl ID : ENSRBIG00000014499
Gene Symbol: LOC108525726
2 Cross references
130 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Tubulin Beta 1 Class Vi

Ensembl ID : ENSRBIG00000043458
Gene Symbol: TUBB1
4 Cross references
186 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Tubulin Beta 2b Class Iib

Ensembl ID : ENSRBIG00000044962
Gene Symbol: TUBB2B
2 Cross references
181 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Tubulin Beta 4a Class Iva

Ensembl ID : ENSRBIG00000028889
Gene Symbol: TUBB4A
4 Cross references
83 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Tubulin Beta 6 Class V

Ensembl ID : ENSRBIG00000030022
Gene Symbol: TUBB6
4 Cross references
141 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Tubulin Beta-7 Chain

Ensembl ID : ENSRBIG00000000892
Gene Symbol: LOC108520633
2 Cross references
23 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).